The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses the impact of next-generation BTK inhibitors (BTKis) on the treatment landscape of chronic lymphocytic leukemia (CLL). Dr Al-Sawaf highlights the ALPINE and ELEVATE-RR trials (NCT03734016; NCT02477696) and the lower risk of cardiovascular toxicities seen with these agents. Dr Al-Sawaf also comments on the exploration of next-generation BTKis as fixed-duration treatments. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
